Ibnsina Pharma results, Fiscal year 2023
Net profit, assets, equity and cash flow for Fiscal year 2023, against the same period a year earlier, from the published financial statements.
Net profit214 millionEGP · +303.2% vs the same period a year earlier
Total assets18.55 billionEGP · +44.2% vs the same period a year earlier
Shareholders' equity1.45 billionEGP · +15.0% vs the same period a year earlier
Operating cash flow126 millionEGP · −65.2% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Fiscal year 2023 was about 214 million EGP, up +303.2% from 52.99 million EGP in Fiscal year 2022.
- Total assets at the end of Fiscal year 2023 were about 18.55 billion EGP, and shareholders' equity about 1.45 billion EGP.
- Operating cash flow for Fiscal year 2023 was positive at 126 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2022Change
Net profit214 million52.99 million+303.2%
Gross profit2.63 billion1.62 billion+62.6%
Total assets18.55 billion12.86 billion+44.2%
Total liabilities17.1 billion11.6 billion+47.4%
Shareholders' equity1.45 billion1.26 billion+15.0%
Total liabilities and equity18.55 billion12.86 billion+44.2%
Operating cash flow126 million362 million−65.2%
Investing cash flow-280 million-1.38 billion+79.7%
Financing cash flow744 million1.09 billion−31.6%
Net change in cash590 million72.67 million+711.3%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy